Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Objective: To conduct a systematic review of real-world (RWD) studies comparing the risk of
major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …

BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …

Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …